PL2688572T3 - Kompozycja farmaceutyczna zawierająca inhibitor hdac i steroid oraz jej stosowanie - Google Patents
Kompozycja farmaceutyczna zawierająca inhibitor hdac i steroid oraz jej stosowanieInfo
- Publication number
- PL2688572T3 PL2688572T3 PL12759898T PL12759898T PL2688572T3 PL 2688572 T3 PL2688572 T3 PL 2688572T3 PL 12759898 T PL12759898 T PL 12759898T PL 12759898 T PL12759898 T PL 12759898T PL 2688572 T3 PL2688572 T3 PL 2688572T3
- Authority
- PL
- Poland
- Prior art keywords
- steroid
- pharmaceutical composition
- hdac inhibitor
- hdac
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161454751P | 2011-03-21 | 2011-03-21 | |
| SE1151196 | 2011-12-15 | ||
| EP12759898.5A EP2688572B1 (en) | 2011-03-21 | 2012-03-20 | A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2688572T3 true PL2688572T3 (pl) | 2017-08-31 |
Family
ID=46879617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12759898T PL2688572T3 (pl) | 2011-03-21 | 2012-03-20 | Kompozycja farmaceutyczna zawierająca inhibitor hdac i steroid oraz jej stosowanie |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20140093565A1 (pl) |
| EP (1) | EP2688572B1 (pl) |
| JP (1) | JP5999724B2 (pl) |
| KR (1) | KR101909313B1 (pl) |
| CN (2) | CN103442715A (pl) |
| BR (1) | BR112013023970B1 (pl) |
| CA (1) | CA2829263C (pl) |
| DK (1) | DK2688572T3 (pl) |
| ES (1) | ES2627020T3 (pl) |
| HU (1) | HUE032100T2 (pl) |
| PL (1) | PL2688572T3 (pl) |
| PT (1) | PT2688572T (pl) |
| WO (1) | WO2012128709A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| CN108542906A (zh) | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
| SG11201401260QA (en) | 2011-11-23 | 2014-07-30 | Novartis Ag | Pharmaceutical formulations |
| EP2916834A1 (en) * | 2012-11-08 | 2015-09-16 | Novartis AG | Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
| EP3222324B1 (en) | 2016-03-23 | 2020-05-13 | Wayne State University | Valproate as a topical anti-fungal treatment |
| CN109069439A (zh) * | 2016-04-21 | 2018-12-21 | 瓦尔库里亚公司 | 用于预处理癌症的组合物和方法 |
| CN109906216A (zh) * | 2016-07-20 | 2019-06-18 | 纽约哥伦比亚大学理事会 | 组蛋白乙酰基转移酶激活剂及其组合物和用途 |
| KR102023845B1 (ko) | 2018-06-07 | 2019-11-04 | 계명대학교 산학협력단 | 히스톤 탈아세틸효소 억제제 및 이의 용도 |
| GB202016193D0 (en) * | 2020-10-13 | 2020-11-25 | Vestlandets Innovasjonsselskap As | Synergistic combinations |
| CN113413389B (zh) * | 2021-07-19 | 2024-03-15 | 成都赜灵生物医药科技有限公司 | 一种组蛋白去乙酰化酶抑制剂的制剂及其制备方法和用途 |
| EP4282408A1 (en) | 2022-05-23 | 2023-11-29 | Valcuria AB | Method for pretreating relapsing cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001285042A1 (en) | 2000-08-18 | 2002-03-04 | The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor |
| EP1293205A1 (en) | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| US20070190022A1 (en) * | 2003-08-29 | 2007-08-16 | Bacopoulos Nicholas G | Combination methods of treating cancer |
| CA2600845A1 (en) * | 2005-03-11 | 2006-09-21 | The Regents Of The University Of Colorado | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
| US20060229237A1 (en) * | 2005-04-07 | 2006-10-12 | Yih-Lin Chung | Treatment of gastrointestinal distress |
| UA99810C2 (ru) | 2005-05-13 | 2012-10-10 | Топотаргет Юк Лимитед | Фармацевтические составы, которые содержат ингибиторы деацетилазы гистонов |
| JP4858803B2 (ja) * | 2005-05-25 | 2012-01-18 | 学校法人東京理科大学 | 抗ｍｒｄ（微少残存白血病）薬 |
| CA2627923C (en) * | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| AU2007342030B2 (en) | 2006-12-29 | 2013-08-15 | Celgene Corporation | Romidepsin-based treatments for cancer |
| WO2009062054A1 (en) * | 2007-11-09 | 2009-05-14 | Novartis Ag | Uses of anti-cd40 antibodies |
| US20100166806A1 (en) * | 2008-12-29 | 2010-07-01 | Aphios Corporation | Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency |
-
2012
- 2012-03-20 DK DK12759898.5T patent/DK2688572T3/en active
- 2012-03-20 ES ES12759898.5T patent/ES2627020T3/es active Active
- 2012-03-20 CA CA2829263A patent/CA2829263C/en active Active
- 2012-03-20 US US14/005,933 patent/US20140093565A1/en not_active Abandoned
- 2012-03-20 PL PL12759898T patent/PL2688572T3/pl unknown
- 2012-03-20 CN CN2012800127938A patent/CN103442715A/zh active Pending
- 2012-03-20 BR BR112013023970-0A patent/BR112013023970B1/pt active IP Right Grant
- 2012-03-20 KR KR1020137027565A patent/KR101909313B1/ko active IP Right Grant
- 2012-03-20 JP JP2014501039A patent/JP5999724B2/ja active Active
- 2012-03-20 HU HUE12759898A patent/HUE032100T2/en unknown
- 2012-03-20 PT PT127598985T patent/PT2688572T/pt unknown
- 2012-03-20 CN CN201910595467.8A patent/CN110279861A/zh active Pending
- 2012-03-20 EP EP12759898.5A patent/EP2688572B1/en active Active
- 2012-03-20 WO PCT/SE2012/050306 patent/WO2012128709A1/en active Application Filing
-
2016
- 2016-03-18 US US15/074,768 patent/US10143697B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012128709A1 (en) | 2012-09-27 |
| BR112013023970A2 (pt) | 2016-12-13 |
| BR112013023970B1 (pt) | 2021-11-16 |
| HUE032100T2 (en) | 2017-08-28 |
| KR101909313B1 (ko) | 2018-10-17 |
| KR20140053871A (ko) | 2014-05-08 |
| CN103442715A (zh) | 2013-12-11 |
| US20140093565A1 (en) | 2014-04-03 |
| US20160271146A1 (en) | 2016-09-22 |
| US10143697B2 (en) | 2018-12-04 |
| CN110279861A (zh) | 2019-09-27 |
| ES2627020T3 (es) | 2017-07-26 |
| CA2829263A1 (en) | 2012-09-27 |
| EP2688572A4 (en) | 2014-08-20 |
| CA2829263C (en) | 2020-05-12 |
| PT2688572T (pt) | 2017-06-02 |
| EP2688572A1 (en) | 2014-01-29 |
| DK2688572T3 (en) | 2017-06-12 |
| JP2014510102A (ja) | 2014-04-24 |
| JP5999724B2 (ja) | 2016-09-28 |
| EP2688572B1 (en) | 2017-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1253692A1 (zh) | 含有hdac抑制劑和環多醣的藥物組合物 | |
| PL2688572T3 (pl) | Kompozycja farmaceutyczna zawierająca inhibitor hdac i steroid oraz jej stosowanie | |
| EP2771321A4 (en) | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH | |
| IL233154A (en) | Compounds, pharmaceuticals containing them and their uses | |
| IL228738B (en) | Antibody against cldn6, a pharmaceutical preparation including it and its use | |
| EP2670733A4 (en) | HDAC HEMMER AND THERAPY PROCESS THEREFOR | |
| IL228322A0 (en) | History of dispiropyrrolidine, preparations containing them and their uses | |
| ME02687B (me) | Dozni oblik otporan na promene | |
| HK1195793A1 (zh) | 結合藥物組合物及其用途 | |
| IL226270A0 (en) | History of hydroxamic acid, preparations containing them and their uses | |
| HK1193100A1 (zh) | 苯基- -氮雜-雙環 己- -基-甲酮及其作為藥物的用途 | |
| EP2718283A4 (en) | INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | |
| EP2694399A4 (en) | DISPENSER OF BANDS AND STRIPS FOR USE THEREWITH | |
| IL222707B (en) | Steroid compounds of 16-chloro- and 16, 16-dichloro-(4-alpha, 4-beta)-17-beta-(2-oxo-2h-pyran-5-yl) and pharmaceutical preparations containing them | |
| EP2685993A4 (en) | PHARMACEUTICAL COMPOSITIONS AND TOPICAL USE THEREOF | |
| EP2560614A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR ADMINISTRATION | |
| EP2720754A4 (en) | LEUKOTOXIN E / D AS NEW INFLAMMATORY INHIBITORS AND MICROBICIDES | |
| IL221737A (en) | Its compound or salt, a pharmaceutical preparation containing it and its uses | |
| EP2776045A4 (en) | HYDROCOLLOID COMPOSITION AND ARTICLE CONTAINING THE SAME | |
| HUE051902T2 (hu) | Duális újrafelvétel inhibitort tartamazó gyógyászati készítmény és eljárás annak elõállítására | |
| ZA201508249B (en) | A pharmaceutical composition containing budesonide and formoterol. | |
| BR112014003419A2 (pt) | partícula e composição contendo a partícula | |
| EP2789613A4 (en) | 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF AND ITS USE | |
| PL393311A1 (pl) | Elektroda wielowarstwowa i jej zastosowanie | |
| GB201009603D0 (en) | Anti-inflammatory agent |